CO2017005573A2 - Composiciones anticancerígenas que comprenden 4-[7-(6-ciano-5-trifluorometilpiridin-3-ilo)-8-oxo-6-tioxo-5,7-diazaspiro[3.4]oct-5-il]-2-fluoro-nmetilbenzamida y un copolímero de poli(met)acrilato” - Google Patents
Composiciones anticancerígenas que comprenden 4-[7-(6-ciano-5-trifluorometilpiridin-3-ilo)-8-oxo-6-tioxo-5,7-diazaspiro[3.4]oct-5-il]-2-fluoro-nmetilbenzamida y un copolímero de poli(met)acrilato”Info
- Publication number
- CO2017005573A2 CO2017005573A2 CONC2017/0005573A CO2017005573A CO2017005573A2 CO 2017005573 A2 CO2017005573 A2 CO 2017005573A2 CO 2017005573 A CO2017005573 A CO 2017005573A CO 2017005573 A2 CO2017005573 A2 CO 2017005573A2
- Authority
- CO
- Colombia
- Prior art keywords
- meth
- poly
- rna
- acrylate copolymer
- prostate cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14196591 | 2014-12-05 | ||
| PCT/US2015/063667 WO2016090101A1 (en) | 2014-12-05 | 2015-12-03 | Anticancer compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2017005573A2 true CO2017005573A2 (es) | 2017-09-29 |
Family
ID=52006905
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2017/0005573A CO2017005573A2 (es) | 2014-12-05 | 2017-06-05 | Composiciones anticancerígenas que comprenden 4-[7-(6-ciano-5-trifluorometilpiridin-3-ilo)-8-oxo-6-tioxo-5,7-diazaspiro[3.4]oct-5-il]-2-fluoro-nmetilbenzamida y un copolímero de poli(met)acrilato” |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US20170360707A1 (enExample) |
| EP (2) | EP3226842B1 (enExample) |
| JP (1) | JP6767368B2 (enExample) |
| KR (1) | KR102348325B1 (enExample) |
| CN (2) | CN115837010B (enExample) |
| AR (1) | AR102924A1 (enExample) |
| AU (1) | AU2015358493B2 (enExample) |
| CA (1) | CA2969661C (enExample) |
| CL (1) | CL2017001372A1 (enExample) |
| CO (1) | CO2017005573A2 (enExample) |
| CR (1) | CR20170217A (enExample) |
| CY (1) | CY1123856T1 (enExample) |
| DK (1) | DK3226842T3 (enExample) |
| EA (1) | EA035988B1 (enExample) |
| ES (2) | ES3021508T3 (enExample) |
| HR (1) | HRP20201902T1 (enExample) |
| HU (1) | HUE051888T2 (enExample) |
| IL (1) | IL252324B (enExample) |
| LT (1) | LT3226842T (enExample) |
| MA (2) | MA41108B1 (enExample) |
| MD (1) | MD3226842T2 (enExample) |
| MX (1) | MX384382B (enExample) |
| NI (1) | NI201700069A (enExample) |
| PL (1) | PL3226842T3 (enExample) |
| PT (1) | PT3226842T (enExample) |
| RS (1) | RS61466B1 (enExample) |
| SG (1) | SG11201704264UA (enExample) |
| SI (1) | SI3226842T1 (enExample) |
| TW (1) | TWI683662B (enExample) |
| UA (1) | UA121123C2 (enExample) |
| WO (1) | WO2016090101A1 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115737643A (zh) | 2012-09-26 | 2023-03-07 | 阿拉贡药品公司 | 用于治疗非转移性去势抵抗性前列腺癌的抗雄激素 |
| EA201791222A1 (ru) | 2014-12-05 | 2017-09-29 | Арагон Фармасьютикалз, Инк. | Противораковые композиции |
| US10285948B2 (en) | 2014-12-05 | 2019-05-14 | Janssen Pharmaceutica Nv | Anticancer compositions |
| MX2020003845A (es) | 2017-10-16 | 2020-11-06 | Aragon Pharmaceuticals Inc | Antiandrógenos para el tratamiento de cáncer de próstata no metastásico resistente a la castración. |
| JP7244536B2 (ja) * | 2018-04-06 | 2023-03-22 | キャプシュゲル・ベルジウム・エヌ・ヴィ | メタクリル酸メチル－メタクリル酸コポリマーからなる低アスペクト比の粒子のための噴霧乾燥方法 |
| WO2020144647A1 (en) | 2019-01-10 | 2020-07-16 | Aragon Pharmaceuticals, Inc. | Pharmaceutical composition comprising apalutamide dispersed in apple sauce |
| CN113711316A (zh) | 2019-01-30 | 2021-11-26 | 詹森药业有限公司 | 基于分子亚型治疗前列腺癌的方法 |
| JP2022523094A (ja) | 2019-01-30 | 2022-04-21 | アラゴン ファーマシューティカルズ，インコーポレイテッド | 転移性去勢感受性前立腺癌の治療のための抗アンドロゲン剤 |
| WO2020239478A1 (en) | 2019-05-28 | 2020-12-03 | Pharma Mar, S.A. | Trabectedin for treating sarcomas based on genomic markers |
| EP4054572A1 (en) | 2019-11-04 | 2022-09-14 | Aragon Pharmaceuticals, Inc. | Androgen receptor inhibitors for the treatment of non-metastatic castration-resistant prostate cancer in subjects with severe hepatic impairment |
| WO2021245285A1 (en) | 2020-06-05 | 2021-12-09 | Janssen Pharmaceutica Nv | Methods of treating prostate cancer based on molecular subtypes |
| TW202228794A (zh) | 2020-09-04 | 2022-08-01 | 美商艾瑞岡醫藥公司 | 用於治療前列腺癌之方法 |
| WO2022195407A1 (en) | 2021-03-19 | 2022-09-22 | Aragon Pharmaceuticals, Inc. | Methods for treating prostate cancer |
| WO2023152611A1 (en) | 2022-02-11 | 2023-08-17 | Aragon Pharmaceuticals, Inc. | Apalutamide and relugolix for the treatment of prostate cancer |
| WO2023209555A1 (en) | 2022-04-26 | 2023-11-02 | Aragon Pharmaceuticals, Inc. | Approved drug products and methods for treating prostate cancer |
| KR20250157532A (ko) | 2023-03-16 | 2025-11-04 | 바이엘 컨수머 케어 악티엔게젤샤프트 | 호르몬 감수성 전립선암의 생화학적 재발이 있는 환자의 치료를 위한 안드로겐 수용체 길항제 |
| WO2026052846A1 (en) | 2024-09-09 | 2026-03-12 | Synthon B.V. | Pharmaceutical formulation comprising apalutamide |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2443040A1 (en) | 2001-04-02 | 2002-10-17 | Nicola Frances Bateman | Solid pharmaceutical composition comprising 4 -cyano-trifluoro-3-(4-fluorophenyl-sulphonyl) -2-hydroxy-2-methylpropiono- m toluidide and pvp |
| WO2003077827A1 (en) * | 2002-03-19 | 2003-09-25 | Nippon Shinyaku Co., Ltd. | Process for producing drug solid dispersion |
| AU2003292509B2 (en) * | 2003-12-15 | 2007-08-02 | Council Of Scientific And Industrial Research | Taste masked pharmaceutical compositions comprising bitter drug and pH sensitive polymer |
| ES2689292T3 (es) * | 2006-03-27 | 2018-11-13 | The Regents Of The University Of California | Modulador del receptor de andrógenos para el tratamiento del cáncer de próstata y enfermedades asociadas con el receptor de andrógenos |
| SG10201907588XA (en) * | 2010-02-16 | 2019-09-27 | Aragon Pharmaceuticals Inc | Androgen Receptor Modulators And Uses Thereof |
| WO2012174436A1 (en) * | 2011-06-15 | 2012-12-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Nuclear receptor modulators and their use for the treatment and prevention of cancer |
| WO2013152342A1 (en) * | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Anti-cancer mtor inhibitor and anti-androgen combination |
| RS60617B1 (sr) | 2012-06-07 | 2020-09-30 | Aragon Pharmaceuticals Inc | Kristalni oblici modulatora receptora androgena |
| US10668156B2 (en) | 2012-06-22 | 2020-06-02 | Basf Se | Active-ingredient-containing solid dispersions based on diethylaminoethyl methacrylate copolymers |
| TWI673051B (zh) * | 2012-09-11 | 2019-10-01 | 美商梅維森前列腺療法有限責任公司 | 恩雜魯它脈（ｅｎｚａｌｕｔａｍｉｄｅ）之調和物 |
| CN115737643A (zh) * | 2012-09-26 | 2023-03-07 | 阿拉贡药品公司 | 用于治疗非转移性去势抵抗性前列腺癌的抗雄激素 |
| DK2945628T3 (da) | 2013-01-15 | 2020-05-04 | Aragon Pharmaceuticals Inc | Androgen receptormodulator i kombination med abirateronacetat og prednison til behandling af prostatacancer |
| SG11201504499VA (en) * | 2013-01-22 | 2015-08-28 | Hoffmann La Roche | Pharmaceutical composition with improved bioavailability |
| WO2014167428A2 (en) | 2013-04-10 | 2014-10-16 | Shilpa Medicare Limited | Amorphous 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide |
| EP3033088A4 (en) * | 2013-08-12 | 2017-03-08 | Tokai Pharmaceuticals, Inc. | Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies |
| MX386859B (es) * | 2014-02-05 | 2025-03-19 | Lek Pharmaceuticals | Composiciones farmacéuticas sólidas de antagonistas de los receptores de andrógenos. |
-
2015
- 2015-12-03 HU HUE15817642A patent/HUE051888T2/hu unknown
- 2015-12-03 CR CR20170217A patent/CR20170217A/es unknown
- 2015-12-03 CA CA2969661A patent/CA2969661C/en active Active
- 2015-12-03 EP EP15817642.0A patent/EP3226842B1/en active Active
- 2015-12-03 SG SG11201704264UA patent/SG11201704264UA/en unknown
- 2015-12-03 MA MA41108A patent/MA41108B1/fr unknown
- 2015-12-03 MA MA055404A patent/MA55404A/fr unknown
- 2015-12-03 ES ES20209559T patent/ES3021508T3/es active Active
- 2015-12-03 PL PL15817642T patent/PL3226842T3/pl unknown
- 2015-12-03 SI SI201531519T patent/SI3226842T1/sl unknown
- 2015-12-03 JP JP2017529637A patent/JP6767368B2/ja active Active
- 2015-12-03 PT PT158176420T patent/PT3226842T/pt unknown
- 2015-12-03 AU AU2015358493A patent/AU2015358493B2/en active Active
- 2015-12-03 EP EP20209559.2A patent/EP3842034B1/en active Active
- 2015-12-03 CN CN202211487545.0A patent/CN115837010B/zh active Active
- 2015-12-03 HR HRP20201902TT patent/HRP20201902T1/hr unknown
- 2015-12-03 UA UAA201707016A patent/UA121123C2/uk unknown
- 2015-12-03 KR KR1020177018240A patent/KR102348325B1/ko active Active
- 2015-12-03 EA EA201791252A patent/EA035988B1/ru unknown
- 2015-12-03 LT LTEP15817642.0T patent/LT3226842T/lt unknown
- 2015-12-03 US US15/533,203 patent/US20170360707A1/en not_active Abandoned
- 2015-12-03 WO PCT/US2015/063667 patent/WO2016090101A1/en not_active Ceased
- 2015-12-03 RS RS20210184A patent/RS61466B1/sr unknown
- 2015-12-03 CN CN201580066192.9A patent/CN106999430A/zh active Pending
- 2015-12-03 DK DK15817642.0T patent/DK3226842T3/da active
- 2015-12-03 MX MX2017007201A patent/MX384382B/es unknown
- 2015-12-03 MD MDE20170153T patent/MD3226842T2/ro not_active IP Right Cessation
- 2015-12-03 ES ES15817642T patent/ES2839128T3/es active Active
- 2015-12-03 TW TW104140458A patent/TWI683662B/zh not_active IP Right Cessation
- 2015-12-04 AR ARP150103980A patent/AR102924A1/es unknown
-
2017
- 2017-05-16 IL IL252324A patent/IL252324B/en unknown
- 2017-05-29 CL CL2017001372A patent/CL2017001372A1/es unknown
- 2017-06-02 NI NI201700069A patent/NI201700069A/es unknown
- 2017-06-05 CO CONC2017/0005573A patent/CO2017005573A2/es unknown
-
2021
- 2021-01-27 CY CY20211100068T patent/CY1123856T1/el unknown
- 2021-12-13 US US17/549,495 patent/US20220151931A1/en not_active Abandoned
-
2024
- 2024-05-10 US US18/661,226 patent/US20240293321A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2017005574A2 (es) | Composiciones anticancerígenas que comprenden 4-[7-(6-ciano-5- trifluorometilpiridin-3-ilo)-8-oxo-6-tioxo-5,7-diazaspiro[3.4]oct-5-ilo]-2-fluoro-nmetilbenzamida, un copolímero de poli(met)acrilato y hpmcas | |
| NI201700069A (es) | Composiciones anticancerosas | |
| CO2017005572A2 (es) | Composiciones anticancerígenas | |
| CL2016001629A1 (es) | Compuestos tricíclicos como agentes anticancerígenos | |
| EA201892828A1 (ru) | Противораковые композиции | |
| SA518392101B1 (ar) | ROR-Gamma مشتقات البنزيميدازول في صورة مُعدلات لـ | |
| NZ728392A (en) | High dosage strength tablets of rucaparib | |
| CL2008003846A1 (es) | Uso de compuestos derivados de 1,2,4-triazolo condensado con heterociclos, los cuales actuan como ligados del receptor de androgeno (ar); compuestos; proceso de preparacion; composicion farmaceutica y el uso de dichos compuestos para el tratamiento del cancer de prostata. | |
| EA201792304A1 (ru) | Комбинированная терапия для лечения рака | |
| MX376062B (es) | Agonistas del receptor muscarinico. | |
| CL2013000018A1 (es) | Compuestos derivados de indolizina , su procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer, entre otros. | |
| MX2020003126A (es) | Derivados de iminopirimidina ciclicos como inhibidores de cinasa. | |
| CL2016001109A1 (es) | Composiciones y métodos útiles en el tratamiento de sintomas del tracto urinario inferior, hiperplasia prostatica benigna disfuncion eréctil | |
| CL2015003595A1 (es) | Inhibidores/antiandrógenos novedosos de cyp17 | |
| ECSP14017586A (es) | Derivados de tetrahidro-quinazolinona | |
| MX2016008042A (es) | Derivados de imidazopirazinona. | |
| CL2008001322A1 (es) | Compuestos derivados de triazolil-aminopirimidina, sustituida con heterociclos; composicion farmaceutica; y uso en el tratamiento del cancer. | |
| WO2017011559A8 (en) | Compositions and methods for treating cancer | |
| MX2020002222A (es) | Arginina deiminasa encapsulada dentro de eritrocitos y su uso en el tratamiento de cancer y la deficiencia de arginasa-1. | |
| GB2519470A (en) | Bicyclic aza compounds as muscarinic M1 receptor agonists | |
| RU2015111612A (ru) | Фармацевтическая композиция на основе 3-(3,5-Диметилпиразол-1-ил)имидазо[1,2-b][1,2,4,5]тетразина в качестве противоопухолевого средства | |
| CL2008001216A1 (es) | Compuestos derivados de pirazol-3-il-amino-pirimidina; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento del cancer. | |
| CL2009001982A1 (es) | Compuestos derivados de pirrolidin-1-il benzonitrilo; y su uso en el tratamiento del cancer de prostata hormono dependiente mediado por el antagonismo del receptor de androgenos. |